Business
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
PARIS & SOUTH SAN FRANCISCO, Calif., March 12, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acqui
About this update from Kezar Life Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":273,"url":"https://media.zenfs.com/en/business-wire.com/232db5614a484ef615fa7b5e5cef57c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vHXmcmCOVVOFVjjpklM2qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/232db5614a484ef615fa7b5e5cef57c6","width":480,"height":273}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/de9c871211af6e62906313ba15397123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iwb31EPySzm8HcMIG7alBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/de9c871211af6e62906313ba15397123","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/h_A8oZ1rb3nFhjZG5ND55g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/de9c871211af6e62906313ba15397123","width":1024,"height":512}}},{"type":"text","content":"Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"PARIS & SOUTH SAN FRANCISCO, Calif., March 12, 2026--(BUSINESS WIRE)--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones.","length":707,"tagName":"p"},{"type":"text","content":"Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, an...